AAAAAA

   
Results: 1-2 |
Results: 2
Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects
Authors: Creagh, T Ruckle, JL Tolbert, DT Giltner, J Eiznhamer, DA Dutta, B Flavin, MT Xu, ZQ
Citation: T. Creagh et al., Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects, ANTIM AG CH, 45(5), 2001, pp. 1379-1386
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis
Authors: Babiker, A Bartlett, J Breckenridge, A Collins, G Coombs, R Cooper, D Creagh, T Cross, A Daniels, M Darbyshire, J Dawson, D DeGruttola, V DeMasi, R Dolin, R Eron, J Fischl, M Grossberg, S Hamilton, J Hammer, S Hartigan, P Henry, K Hill, A Hughes, M Kahn, J Katlama, C Katzenstein, D Kim, S Mildvan, D Montaner, J Moore, M Neaton, J O'Brien, W Ribaudo, H Richman, D Saag, M Salgo, M Saravolatz, L Schooley, R Seligmann, M Staszewski, S Struthers, L Tierney, C Tsiatis, A Welles, S
Citation: A. Babiker et al., Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis, AIDS RES H, 16(12), 2000, pp. 1123-1133
Risultati: 1-2 |